Diabetes Knowledge into Practice Podcast

Join Prof. Francesco Giorgino and Dr. Darren McGuire as they discuss personalisation of treatment for patients with both type 2 diabetes and cardiovascular disease.

For more free education, go to ⁠⁠⁠⁠⁠diabetes.knowledgeintopractice.com⁠⁠⁠⁠⁠⁠, where you can see all past episodes of the podcast as well as other free CME resources. Follow us on Twitter (⁠⁠⁠⁠⁠@dkipractice⁠⁠⁠⁠⁠⁠) or connect on ⁠⁠⁠⁠⁠LinkedIn⁠⁠⁠⁠⁠⁠.

Faculty disclosures

Prof. Francesco Giorgino

Grants or contracts: Eli Lilly, Roche Diabetes Care

Consulting: Eli Lilly, Novo Nordisk

Honoraria for lectures, presentations and education events: Astra-Zeneca, Boehringer-Ingelheim

Advisory boards: Eli Lilly, Lifescan, Merck Sharp & Dohme, Medimmune

Leadership or fiduciary role in other board: EASD/EFSD, (SIE), Fo.Ri SIE

Receipt of equipment, materials, drugs, medical writing, gifts or other services: AstraZeneca, Eli Lilly, Novo Nordisk

Unlabelled use of drugs or devices: Roche Diabetes Care, Sanofi

Dr. Darren K. McGuire

Clinical trial leadership:

- Former: Esperion, AstraZeneca, CSL Behring

- Current: Novo Nordisk, Lilly USA, Pfizer, Boehringer Ingelheim, NewAmsterdam

Consultancy:

- Former: Merck & Co

- Current: Lilly USA, Boehringer Ingelheim, Novo Nordisk, Bayer, Lexicon, Altimmune, Esperion, Intercept Pharmaceuticals, Applied Therapeutics

Funding Information:

This independent educational activity is supported by an educational grant from Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Novo Nordisk A/S, has had no influence on the content of this education.

Accreditation information

Liberum IME staff, ACHL staff and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

ACHL requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships within 24 months (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any ineligible companies. All relevant financial relationships have been mitigated prior to this activity.

This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires its speakers to disclose that a product is not labeled for the use under discussion.

Discussion of Off-Label, Investigational, or Experimental Drug Use: None

Join Prof. Francesco Giorgino and Dr. Shehla Shaikh as they discuss strategies to help support type 2 diabetes patients during cultural events, such as observation of Ramadan.

For more free education, go to ⁠⁠⁠⁠diabetes.knowledgeintopractice.com⁠⁠⁠⁠⁠, where you can see all past episodes of the podcast as well as other free CME resources. Follow us on Twitter (⁠⁠⁠⁠@dkipractice⁠⁠⁠⁠⁠) or connect on ⁠⁠⁠⁠LinkedIn⁠⁠⁠⁠⁠.

Prof. Francesco Giorgino

Grants or contracts: Eli Lilly, Roche Diabetes Care

Consulting: Eli Lilly, Novo Nordisk

Honoraria for lectures, presentations and education events: Astra-Zeneca, Boehringer-Ingelheim

Advisory boards: Eli Lilly, Lifescan, Merck Sharp & Dohme, Medimmune

Leadership or fiduciary role in other board: EASD/EFSD, (SIE), Fo.Ri SIE

Receipt of equipment, materials, drugs, medical writing, gifts or other services: AstraZeneca, Eli Lilly, Novo Nordisk

Unlabelled use of drugs or devices: Roche Diabetes Care, Sanofi

Dr. Shehla Shaikh

Dr. Shaikh declares no current financial conflict of interest

Funding Information:

This independent educational activity is supported by an educational grant from Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Novo Nordisk A/S, has had no influence on the content of this education.

Accreditation information

Liberum IME staff, ACHL staff and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

ACHL requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships within 24 months (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any ineligible companies. All relevant financial relationships have been mitigated prior to this activity.

This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires its speakers to disclose that a product is not labeled for the use under discussion.

Discussion of Off-Label, Investigational, or Experimental Drug Use: None

Join Prof. Francesco Giorgino and Dr. Alice Cheng for a discussion on the importance of being culturally sensitive during shared decision-making in type 2 diabetes care.

For more free education, go to ⁠⁠diabetes.knowledgeintopractice.com⁠⁠⁠, where you can see all past episodes of the podcast as well as other free CME resources. Follow us on Twitter (⁠⁠@dkipractice⁠⁠⁠) or connect on ⁠⁠LinkedIn⁠⁠⁠.

Faculty disclosures

Prof. Francesco Giorgino

Grants or contracts: Eli Lilly, Roche Diabetes Care

Consulting: Eli Lilly, Novo Nordisk

Honoraria for lectures, presentations and education events: Astra-Zeneca, Boehringer-Ingelheim

Advisory boards: Eli Lilly, Lifescan, Merck Sharp & Dohme, Medimmune

Leadership or fiduciary role in other board: EASD/EFSD, (SIE), Fo.Ri SIE

Receipt of equipment, materials, drugs, medical writing, gifts or other services: AstraZeneca, Eli Lilly, Novo Nordisk

Unlabelled use of drugs or devices: Roche Diabetes Care, Sanofi

Dr. Alice Cheng

Advisory Board: Abbott, AstraZeneca, Bayer

Speakers Bureau: Abbott, Amgen, AstraZeneca, Bausch, Bayer

Funding Information:

This independent educational activity is supported by an educational grant from Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Novo Nordisk A/S, has had no influence on the content of this education.

Accreditation information

Liberum IME staff, ACHL staff and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

ACHL requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships within 24 months (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any ineligible companies. All relevant financial relationships have been mitigated prior to this activity.

This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires its speakers to disclose that a product is not labeled for the use under discussion.

Discussion of Off-Label, Investigational, or Experimental Drug Use: None

Join Prof. Francesco Giorgino and Dr. Erika Bezerra Parente as they identify some takeaways from EASD 2023, including data and discussions on treatment non-adherence, SGLT2 inhibitors, and stigma

For more free education, go to ⁠diabetes.knowledgeintopractice.com⁠⁠, where you can see all past episodes of the podcast as well as other free CME resources. Follow us on Twitter (⁠@dkipractice⁠⁠) or connect on ⁠LinkedIn⁠⁠.

Faculty disclosures

Prof. Francesco Giorgino

Grants or contracts: Eli Lilly, Roche Diabetes Care

Consulting: Eli Lilly, Novo Nordisk

Honoraria for lectures, presentations and education events: Astra-Zeneca, Boehringer-Ingelheim

Advisory boards: Eli Lilly, Lifescan, Merck Sharp & Dohme, Medimmune

Leadership or fiduciary role in other board: EASD/EFSD, (SIE), Fo.Ri SIE

Receipt of equipment, materials, drugs, medical writing, gifts or other services: AstraZeneca, Eli Lilly, Novo Nordisk

Unlabelled use of drugs or devices: Roche Diabetes Care, Sanofi

Dr. Erika Bezerra Parente

Honoraria for lectures, presentations and education events: Sanofi

Funding Information:

This independent educational activity is supported by an educational grant from Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Novo Nordisk A/S, has had no influence on the content of this education.

Accreditation information

Liberum IME staff, ACHL staff and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

ACHL requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships within 24 months (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any ineligible companies. All relevant financial relationships have been mitigated prior to this activity.

This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires its speakers to disclose that a product is not labeled for the use under discussion.

Discussion of Off-Label, Investigational, or Experimental Drug Use: None

In this epsisode Prof. Francisco Giorgino & Dr. Vanita Aroda explore how vital it is that we aim to control more than blood glucose levels when treating type 2 diabetes patients and whether we should strive for a balance by achieving weight, cardiovascular and renal targets as well.

For more free education, go to diabetes.knowledgeintopractice.com⁠, where you can see all past episodes of the podcast as well as other free CME resources. Follow us on Twitter (@dkipractice⁠) or connect on LinkedIn⁠.

Disclosures

Prof. Francisco Giorgino:

Grants or contracts: Eli Lilly, Roche Diabetes Care

Consulting: Eli Lilly, Novo Nordisk

Honoraria for lectures, presentations and education events: Astra-Zeneca, Boehringer-Ingelheim

Advisory boards: Eli Lilly, Lifescan, Merck Sharp & Dohme, Medimmune

Leadership or fiduciary role in other board: EASD/EFSD, (SIE), Fo.Ri SIE

Receipt of equipment, materials, drugs, medical writing, gifts or other services: AstraZeneca, Eli Lilly, Novo Nordisk

Unlabelled use of drugs or devices: Roche Diabetes Care, Sanofi

Dr. Vanita Aroda:

Consulting: Applied Therapeutics, Fractyl, Pfizer, Novo Nordisk, Sanofi

Research Support: Applied Therapeutics, Eli Lilly, Fractyl, Novo Nordisk, Sanofi

Target Audience:

Specialty: Primary care physicians (PCPs), endocrinologists, cardiologists, diabetologists

Geographic: Global (ex US and UK audiences)

Funding Information:

This independent educational activity is supported by an educational grant from Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Novo Nordisk A/S, has had no influence on the content of this education.